Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Common Equity for 4 consecutive years, with $87.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 47.95% year-over-year to $87.8 million; the TTM figure through Mar 2026 stood at $87.8 million (down 47.95% YoY), while the FY2025 annual figure was $110.0 million, down 41.08% from the prior year.
• Common Equity eased to $87.8 million in Q1 2026 per ARTV's latest filing, from $110.0 million in the prior quarter.
• Across five years, Common Equity topped out at $201.0 million in Q3 2024 and bottomed at -$191.1 million in Q2 2024.
• Historically, Common Equity has averaged $15.8 million across 4 years, with a median of $98.9 million in 2025.
• Annual changes were most pronounced in 2024 — Common Equity jumped 232.71% — and 2026, when it slumped 47.95%.
• Artiva Biotherapeutics' Common Equity stood at -$162.0 million in 2023, then jumped by 215.2% to $186.6 million in 2024, then sank by 41.08% to $110.0 million in 2025, then slipped by 20.12% to $87.8 million in 2026.
• Business Quant data shows ARTV's Common Equity at $87.8 million in Q1 2026, $110.0 million in Q4 2025, and $129.2 million in Q3 2025.